Lupin gets USFDA nod for biosimilar drug
Lupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at Lupins Pune facility. Armlupeg aims to reduce infection risk from chemotherapy, and Lupin plans to expand its US biosimilar portfolio. The US market for Pegfilgrastim is worth over $1.29 billion annually.
23 C